Gilead's Hepcludex FDA Approval Marks Milestone | Pharma and Biotech Daily - Pharma and BioTech Daily

Summary5 min read

Episode Overview

Title: Gilead's Hepcludex FDA Approval Marks Milestone
Podcast: Pharma and BioTech Daily
Date: May 27, 2026
Host: Pharma and BioTech News

This episode delivers a succinct roundup of the most significant pharmaceutical and biotech news shaping the industry. The main focus is the US FDA’s approval of Gilead’s Hepcludex for hepatitis D, alongside regulatory, business, and R&D highlights from other leading companies such as Pfizer, Astellas, Lantheus, NiaWave, SK Bioscience, Eli Lilly, AstraZeneca, Daiichi Sankyo, and Moderna. The tone is informative and concise, targeting industry professionals, scientists, and investors.

Key Discussion Points & Insights

1. Gilead’s Hepcludex Approval: A Milestone for Hepatitis D

[00:19 – 01:23]

First FDA-Approved Therapy for Chronic Hepatitis D:
The episode opens with the landmark FDA approval of Gilead Sciences’ Hepcludex, the first therapy targeting chronic hepatitis D—a previously underserved condition.
Significance:
- “This approval marks a comeback for Gilead after previous setbacks due to manufacturing and delivery issues, highlighting the critical importance of addressing regulatory feedback.” (Host, 00:34)
- Underscores the persistence required to overcome regulatory and operational challenges to bring crucial medicines to market.

2. Pfizer Expands Braftovi (Encorafenib): Global Oncology Strategy

[01:24 – 01:47]

New Regulatory Approvals:
Pfizer’s Braftovi (encorafenib) expands with new EU and Canadian approvals for colorectal cancer, extending its reach beyond the US.
Industry Trend:
- “This broadening geographic footprint reflects a broader industry trend where companies aim to maximize the therapeutic impact of oncology drugs across diverse patient populations.” (Host, 01:35)

3. Astellas Pharma: Navigating the Patent Cliff

[01:48 – 02:08]

Response to Patent Expiry:
Astellas addresses looming patent expiration for Xtandi by pursuing licensing deals and cost cutting.
Strategic Takeaway:
Balancing acquisition and operational efficiency is highlighted as a “widespread industry strategy … to sustain growth.” (Host, 01:56)

4. Radiopharmaceutical Sector Activity

[02:09 – 02:41]

Deals & Investments:
- Lantheus under potential acquisition by Curium for $7B indicates sharp industry interest in radiopharmaceuticals due to their tumor-targeting precision.
- NiaWave invests $75M in a Michigan isotope plant to produce actinium-225 (for cancer therapy) by 2028.
Memorable Quote:
“This potential deal underscores growing interest in radiopharmaceuticals due to their precision in targeting specific cancer types.” (Host, 02:19)

5. Regulatory Reform & International Collaborations

[02:42 – 03:17]

FDA Initiatives:
Despite leadership changes, programs like the National Priority Voucher illustrate commitment to “streamlining drug approvals and fostering innovation.” (Host, 02:53)
Vaccine Accessibility:
SK Bioscience teams with Colombia to locally produce the chickenpox vaccine, enhancing access via tech transfer.

6. Eli Lilly’s Infectious Disease Expansion and Strategic Acquisitions

[03:18 – 04:22]

Acquisition Spree:
- The company acquires Curevo, Limitek Biologics, and one more vaccine firm for up to $3.8B, targeting infectious disease pipeline growth.
- “This strategic acquisition underscores a commitment to enhancing capabilities in infectious diseases, a field that has gained focus post COVID 19 pandemic.” (Host, 03:47)
Expertise Buildup:
Hiring of FDA’s Peter Marks enhances vaccine domain knowledge.
Industry Validation:
Eli Lilly recognized as an innovation leader by Idea Pharma.

7. Gene Editing & Cholesterol Management

[04:23 – 04:59]

Verve Therapeutics Collaboration:
Lilly preps for Phase 2 trials of a gene editor for cholesterol, with results similar to PCSK9 inhibitors.
Significance:
“A significant development from Lilly's pipeline includes promising results from their base editor technology acquired through Verve Therapeutics, an exciting breakthrough…” (Host, 04:39)

8. Oncology: Targeted & Precision Therapies See Results

[05:00 – 05:33]

FDA Approval:
AstraZeneca & Daiichi Sankyo’s Datroway antibody drug conjugate earns FDA approval for triple-negative breast cancer (first-line, targets TROP2).
Combination Therapy Advances:
Cura Oncology’s combo (Darlafarnib + Crozati) achieves 69% response rate in KRAS G12C-mutated tumors (Phase 1).
Precision Medicine Highlight:
“Emphasizing precision medicine's potential in targeting specific genetic mutations driving cancer progression.” (Host, 05:25)

9. Obesity & Metabolic Disease Breakthroughs

[05:34 – 05:45]

Lilly’s Retatrutide:
Phase 3 success with surgery-like outcomes for obesity; the drug is a triple hormone receptor agonist illustrating next-gen metabolic therapies.

10. Vaccines and Pandemic Learnings

[05:46 – 06:09]

Moderna’s mRNA Flu Vaccine:
M. Fluciva up for FDA advisory review as an influenza preventative for older adults—MRNA platform expands from COVID-19 to flu.

11. Broader Industry Dynamics

[06:10 – End]

M&A and Clinical Milestones:
Persistent focus on integrating cutting-edge science into commercial therapies and global access strategies.
ASCO Highlights to Watch:
Summit Therapeutics and IKESO’s Keytrude analogs could reshape cancer therapy paradigms.
Closing Thought:
“As pharmaceutical landscapes continue evolving rapidly through scientific strides tempered by regulatory hurdles, the current environment promises significant advancements, offering new hope while demanding strategic agility within healthcare sectors.” (Host, 06:40)

Notable Quotes & Memorable Moments

On Gilead’s Resilience:
“This approval marks a comeback for Gilead after previous setbacks due to manufacturing and delivery issues, highlighting the critical importance of addressing regulatory feedback.” (Host, 00:34)
On Strategic Acquisitions:
“Acquiring three vaccine-focused biotech firms signifies substantial investment in expanding its vaccine portfolio, a move aligned with global immunization strategies.” (Host, 04:17)
On Precision Medicine:
“Emphasizing precision medicine's potential in targeting specific genetic mutations driving cancer progression.” (Host, 05:25)
On Industry Agility:
“The current environment promises significant advancements, offering new hope while demanding strategic agility within healthcare sectors.” (Host, 06:40)

Timestamps for Important Segments

Gilead’s Hepcludex Approval: 00:19 – 01:23
Pfizer’s Braftovi Approvals: 01:24 – 01:47
Astellas Patent Strategies: 01:48 – 02:08
Radiopharma Deals & Isotope Investment: 02:09 – 02:41
Regulatory and International Partnerships: 02:42 – 03:17
Eli Lilly Infectious Disease Acquisitions: 03:18 – 04:22
Gene Editing for Cholesterol: 04:23 – 04:59
Targeted Oncology Therapies: 05:00 – 05:33
Obesity Drug Progress: 05:34 – 05:45
MRNA Flu Vaccine Preview: 05:46 – 06:09
Industry Outlook & Conference Highlights: 06:10 – End

Conclusion

This tightly packed briefing spotlights major industry approvals, business strategies, and pipeline progress, with a focus on resilience (Gilead), precision (oncology and radiopharma), and pandemic-driven R&D expansions (Eli Lilly and Moderna). The episode clearly tracks market shifts, regulatory aspirations, and R&D frontiers—offering valuable illumination for anyone invested in the future of pharma and biotech.

Loading summary

Transcript2 lines

[00:00]
A
Biotech Daily is now open for sponsors and Job of the Week listings. If you want to reach biotech or pharma operators, scientists, founders and investors, you can book a single episode, a full week, or promote an open role, all directly by visiting sponsor O with AI that's sponsor OWITH AI.
[00:20]
B
Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries continues to evolve with significant scientific advancements, regulatory breakthroughs and strategic maneuvers that are reshaping drug development and patient care. One of the noteworthy developments is the US FDA's recent approval of Gilead Sciences Hep Cludex for hepatitis D. This approval marks a comeback for Gilead after previous setbacks due to manufacturing and delivery issues, highlighting the critical importance of addressing regulatory feedback. It's a testament to persistence in overcoming manufacturing challenges to ensure vital therapies reach those in need. This approval signifies a milestone as it's the first FDA approved therapy targeting chronic hepatitis D virus infection, a niche condition with limited treatment options. Similarly, Pfizer's Braftovi in Corafenib is expanding its global reach beyond US borders with regulatory approvals in the EU and Canada for colorectal cancer treatment. This broadening geographic footprint reflects a broader industry trend where companies aim to maximize the therapeutic impact of oncology drugs across diverse patient populations. Meanwhile, Astellas Pharma is navigating the looming patent cliff for its prostate cancer drug Xtandi by actively pursuing new licensing deals and implementing cost cutting measures. This dual approach underscores a widespread industry strategy where companies balance acquisitions with operational efficiency to sustain growth. In the radiopharmaceutical sector, there's notable activity with Lantheus holdings possibly being acquired by Curium for $7 billion. This potential deal underscores growing interest in radiopharmaceuticals due to their precision in targeting specific cancer types. Complementing this is NiaWave's $75 million investment in a radiopharmaceutical isotope plant in Michigan set to produce actinium 225 by 2028, an isotope crucial for targeted cancer therapies. Regulatory landscapes are also in flux with continued reforms at the fda. Despite leadership changes. Initiatives like the Commissioner's National Priority Voucher Program illustrate regulatory body's commitment to streamlining drug approvals and fostering innovation. On an international note, SK Bioscience is partnering with Colombia to locally produce the chickenpox vaccine sky varicella, enhancing vaccine accessibility through technology transfer. Similarly, Eli Lilly's acquisition spree in infectious disease research signals a robust push toward expanding its R and D pipeline for viral and bacterial pathogens. Eli Lilly has announced plans to acquire Curevo, Limitek Biologics and another vaccine company for up to $3.8 billion. This strategic acquisition underscores a commitment to enhancing capabilities in infectious diseases, a field that has gained focus post COVID 19 pandemic. By integrating these companies, Eli Lilly aims to leverage their platforms and expertise for advanced therapeutic solutions against infectious diseases. In gene editing, Eli Lilly is preparing for a phase two trial of a lipid lowering gene editor from Verve Therapeutics showing promising cholesterol reductions akin to PCSK9 inhibitors. This highlights gene editing's potential in addressing cardiovascular diseases. A significant development from Lilly's pipeline includes promising results from their base editor technology acquired through Verve Therapeutics, an exciting breakthrough suggesting substantial potential for gene editing technologies addressing genetic disorders like high cholesterol. In oncology AstraZeneca and Daiichi Sankyo's Datroway gained FDA approval for triple negative breast cancer as a first line treatment. This antibody drug conjugate targets TROP2, demonstrating the potential of targeted therapy in difficult to treat cancers. Cura Oncology's combination therapy featuring Darlafarnib and Crozati showed up to a 69% response rate in crass G12C mutated solid tumor tumors during phase one trials, emphasizing precision medicine's potential in targeting specific genetic mutations driving cancer progression. In obesity management, Eli Lilly's retatrutide achieved Phase three success with bariatric surgery. Like outcomes, the drug acts as a triple hormone receptor agonist, showcasing advancements in metabolic therapies targeting obesity, a condition linked with numerous comorbidities. Moderna's M. Fluciva is poised for an FDA Advisory committee review as an influenza preventative for older adults, an extension of Moderna's MRNA technology initially used against COVID 19. Collectively, these developments highlight an industry leveraging cutting edge science and technology to tackle complex medical challenges. As pharmaceutical giants like Eli Lilly consolidate their positions through acquisitions and research collaborations, transformative advancements promise to reshape patient care across various therapeutic areas. These initiatives not only reflect the industry's dynamic nature but also its pivotal role in addressing unmet medical needs worldwide. Eli Lilly's recent strategic acquisitions underscore its commitment to advancing pharmaceutical innovations, particularly in vaccines and cholesterol management sectors. Acquiring three vaccine focused biotech firms signifies substantial investment in expanding its vaccine portfolio, a move aligned with global immunization strategies. This follows hiring Peter Marks from the fda, indicating a strategic focus on bolstering expertise within the vaccine domain. The company has been recognized by Idea Pharma as a leader in pharmaceutical innovation, a testament to its robust pipeline and successful integration of scientific advancements into marketable therapies across oncology landscapes. Highlighted at ASCO conferences are exciting potentials like Summit Therapeutics and IKESO's potential Keytrude arrivals that could reshape cancer treatment paradigms if proven effective. As pharmaceutical landscapes continue evolving rapidly through scientific strides tempered by regulatory hurdles, the current environment promises significant advancements, offering new hope while demanding strategic agility within healthcare sectors. Globally.